Atara Biotherapeutics IncNASDAQ:ATRA
- LAST PRICE12.1800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots12.2000/ 3
- Ask / Lots13.1200/ 2
- Open / Previous Close--- / 12.1800
- Day Range---
- 52 Week Range
- Volume213
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATRA |
|---|---|---|
| 09:32 ET | 338 | 12.25 |
| 09:39 ET | 497 | 12.5881 |
| 09:44 ET | 759 | 12.04 |
| 09:46 ET | 1062 | 12.135 |
| 09:48 ET | 360 | 12.01 |
| 09:57 ET | 400 | 12.085 |
| 10:33 ET | 456 | 12.09 |
| 10:36 ET | 5000 | 12.15 |
| 10:49 ET | 403 | 12.105 |
| 11:00 ET | 200 | 12.25 |
| 11:05 ET | 350 | 12.38 |
| 11:07 ET | 2046 | 12.195 |
| 11:14 ET | 100 | 12.05 |
| 11:50 ET | 104 | 12.155 |
| 12:01 ET | 100 | 12.19 |
| 12:08 ET | 100 | 12.28 |
| 12:15 ET | 1232 | 12.345 |
| 12:17 ET | 900 | 12.23 |
| 12:30 ET | 100 | 12.365 |
| 12:32 ET | 105 | 12.2717 |
| 12:33 ET | 100 | 12.355 |
| 12:42 ET | 180 | 12.281 |
| 12:44 ET | 200 | 12.43 |
| 01:00 ET | 1000 | 12.42 |
| 01:02 ET | 100 | 12.27 |
| 01:04 ET | 1087 | 12.225 |
| 01:06 ET | 300 | 12.21 |
| 01:24 ET | 100 | 12.07 |
| 01:31 ET | 300 | 12.26 |
| 01:40 ET | 500 | 12.17 |
| 01:44 ET | 500 | 12.19 |
| 01:51 ET | 300 | 12.185 |
| 02:00 ET | 133 | 12.18 |
| 02:09 ET | 100 | 12.095 |
| 02:16 ET | 100 | 12.06 |
| 02:25 ET | 160 | 12.0384 |
| 02:32 ET | 146 | 12.057 |
| 02:38 ET | 100 | 12.055 |
| 02:41 ET | 100 | 12.1 |
| 02:48 ET | 100 | 12.21 |
| 02:50 ET | 582 | 12.1 |
| 02:52 ET | 100 | 12.185 |
| 02:56 ET | 200 | 12.0516 |
| 03:03 ET | 200 | 12.1176 |
| 03:15 ET | 200 | 12.19 |
| 03:19 ET | 100 | 12.06 |
| 03:21 ET | 500 | 12.12 |
| 03:28 ET | 500 | 12.12 |
| 03:30 ET | 3550 | 12.01 |
| 03:32 ET | 1446 | 12.01 |
| 03:42 ET | 965 | 12.1 |
| 03:44 ET | 200 | 12.12 |
| 03:46 ET | 100 | 12.12 |
| 03:48 ET | 200 | 12.1 |
| 03:51 ET | 100 | 12.085 |
| 03:55 ET | 100 | 12.085 |
| 03:57 ET | 200 | 12.105 |
| 04:00 ET | 653 | 12.18 |
Nov 27, 2024
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference, from 4:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 13, 2024
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Atara Biotherapeutics 3Q Loss/Shr $2.93 >ATRA, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesSidoti Events, LLC's Virtual November Micro-Cap Conference, from 8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Atara Biotherapeutics Inc | 70.6M | -0.5x | --- |
Clearside Biomedical Inc | 81.2M | -2.4x | --- |
CervoMed Inc | 75.6M | -5.7x | --- |
Cue Biopharma Inc | 77.3M | -1.3x | --- |
Ikena Oncology Inc | 92.3M | -1.4x | --- |
Kezar Life Sciences Inc | 54.0M | -0.6x | --- |
Company Information
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Contact Information
- Headquarters
- 2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320
- Phone
- 805-623-4244
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Pascal Touchon
- President, Chief Executive Officer, Director
- Anhco Nguyen
- Chief Financial Officer, Executive Vice President
- Eric Hyllengren
- Executive Vice President - Global Head Regulatory Affairs and Quality
- Jill Henrich
- Lead Independent Director
- Carol Gallagher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.6M |
|---|---|
Revenue (TTM) | $100.4M |
Shares Outstanding | 5.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $-26.44 |
Book Value | $-23.31 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -130.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
